Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers

Clicks: 254
ID: 270635
1999
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
Zanamivir is a well tolerated drug. The low level of absorption of the drug after inhaled administration results in low serum concentrations, and therefore there is modest systemic exposure to zanamivir after inhalation. Zanamivir is not metabolised, and the potential for clinically relevant drug-dr ā€¦
Reference Key
lm1999clinicalpharmacokinetics Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Cass LM;Efthymiopoulos C;Bye A;;
Journal clinical pharmacokinetics
Year 1999
DOI DOI not found
URL
http://www.ncbi.nlm.nih.gov/pubmed/10429835
Keywords
injections Administration National Center for Biotechnology Information NCBI NLM MEDLINE humans pubmed abstract nih national institutes of health national library of medicine safety adult female male adolescent middle aged Comparative Study Clinical Trial Randomized Controlled Trial Double-Blind Method reference values inhalation antiviral agents / administration & dosage oral intravenous intranasal guanidines pyrans zanamivir neuraminidase / antagonists & inhibitors pmid:10429835 doi:10.2165/00003088-199936001-00001 l m cass c efthymiopoulos a bye antiviral agents / pharmacokinetics* biological availability sialic acids / administration & dosage sialic acids / pharmacokinetics*

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.